Drugs / Abiraterone acetate
Abiraterone acetate
English name Abiraterone
also known as
abiraterone · Zytiga · CB7630 · JNJ-212082 · JNJ-589485 · ATRS-2002 · BR9004 · BR9004-1 · +3 more
Small molecule targets AR, CYP17A1, CYP2D6 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | ZYTIGA | — | 2012-12-10 – 2019-06-03 | fda.gov ↗ |
| Approved | EU (EMA) | Zytiga | — | 2011-09-05 | europa.eu ↗ |
| Approved | US (FDA) | ZYTIGA | — | 2011-04-28 | fda.gov ↗ |
Trials 221 · started per year
today
US approved 2011
EU approved 2011
2
2
4
2
7
4
11
20
14
18
5
12
15
10
13
12
12
6
12
14
17
6
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04735913 | May → Aug 2020 | — | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03511196 | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02415621 | Apr 2015 → Aug 2019 overdue | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 149 trials | ||||||
| Phase 1 | NCT07570979 | May 2026 → Jun 2030 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07140900 | Oct 2025 → Mar 2028 expected | metastatic prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06421935 | Aug 2024 → Feb 2027 expected | neoplasm | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06014853 | Aug → Oct 2023 | prostate cancer | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05733351 | Aug 2023 → Jun 2025 | prostate adenocarcinoma | Emory University | Terminated | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05276492 | Jan 2023 → Nov 2024 | metastatic prostate carcinoma, prostate adenocarcinoma | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT04879589 | Sep 2022 → Apr 2023 | prostate carcinoma | Syneos Health | Withdrawn | No outcome recorded |
| Phase 1 | NCT05413421 | Jun 2022 → Jun 2027 expected | metastatic prostate carcinoma | ORIC Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06193993 | Nov 2021 → Sep 2023 overdue | castration-resistant prostate carcinoma, metastatic malignant neoplasm | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04889651 | Apr → Jun 2021 | prostate cancer | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04666129 | Feb 2021 → May 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04577833 | Nov 2020 → Oct 2021 overdue | prostate neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04296578 | Oct 2020 → Oct 2022 | castration-resistant prostate carcinoma | Stanford University | Withdrawn | No outcome recorded |
| Phase 1 | NCT04399876 | Jun 2020 → Aug 2027 expected | prostate cancer | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04221542 | Mar 2020 → Mar 2030 expected | prostate cancer | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT04291664 | Jan 2020 → Jan 2023 | prostate cancer | DisperSol Technologies, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04179396 | Dec 2019 → Nov 2021 | castration-resistant prostate carcinoma | pharmaand GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03569280 | Nov 2019 → Jan 2023 | castration-resistant prostate carcinoma | Kangpu Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04108247 | Sep 2019 → Jun 2023 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04087174 | Aug 2019 → Jun 2021 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04295161 | Jun → Nov 2019 | — | Zentiva, k.s. | Completed | No outcome recorded |
| Phase 1 | NCT02574910 | Aug 2017 → Jun 2023 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT03150056 | Jul 2017 → Jul 2020 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02924766 | Oct 2016 → Jul 2019 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02883166 | Aug 2016 → Mar 2019 | prostate cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02740985 | Jun 2016 → Dec 2020 | castration-resistant prostate carcinoma, colorectal carcinoma, high grade malignant neoplasm, non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02123758 | Jul 2014 → Jun 2016 overdue | castration-resistant prostate carcinoma | Aragon Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02730975 | May 2014 → Oct 2020 | prostate cancer | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 1 | NCT01897389 | Jul → Sep 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01913015 | Jul 2013 → Jun 2014 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT01873001 | May → Jul 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01678573 | Jul → Sep 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01655147 | Jan → Mar 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01588782 | Jan → Feb 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01516047 | Jan → Sep 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01575587 | Jan → May 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01495910 | Dec 2011 → Feb 2013 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT01400555 | Sep 2011 → May 2014 | prostate cancer | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01362764 | May → Jun 2011 | — | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01186484 | Jun 2010 → Oct 2014 | prostate cancer | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01017939 | Jan → Jun 2010 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01798628 | Sep → Oct 2009 | — | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02001571 | Aug 2009 → Apr 2010 | prostate cancer | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01715259 | Aug 2009 → Jan 2010 | impaired renal function disease | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00910754 | May → Nov 2009 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00600535 | Jul 2007 → Mar 2012 | prostate neoplasm | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01664728 | Apr 2007 → Feb 2009 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/221 trials | ||||||
| Phase 1/2 | NCT07190300 | Jan 2026 → Aug 2032 expected | prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07198633 | Nov 2025 → Dec 2026 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06863272 | Jul 2025 → Apr 2031 expected | castration-resistant prostate carcinoma, metastatic neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06329830 | Oct 2024 → Oct 2026 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Baptist Health South Florida | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06568094 | Sep 2024 → Jun 2026 overdue | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06457919 | Jun 2024 → Jun 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05914116 | Aug 2023 → Dec 2027 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05367440 | Jun 2022 → Apr 2031 expected | metastatic prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05067140 | Sep 2021 → May 2027 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04631601 | Jan 2021 → Oct 2023 | prostate carcinoma | Amgen | Terminated | No outcome recorded |
| Phase 1/2 | NCT03587285 | Sep 2018 → Jul 2021 | prostate neoplasm | Guangzhou University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03480646 | Nov 2017 → Feb 2021 | castration-resistant prostate carcinoma | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT02861573 | Nov 2016 → Oct 2027 expected | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02049190 | Feb 2014 → Jul 2017 | prostate carcinoma | Arno Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01780220 | Dec 2012 → Jan 2022 | prostate adenocarcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 1/2 | NCT01685268 | Sep 2012 → Jul 2014 | prostate cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01688492 | Sep 2012 → Sep 2026 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01511536 | Mar 2012 → Jul 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT00755885 | Oct 2008 → Jun 2016 | breast cancer | Cancer Research UK | Completed | No outcome recorded |
| Phase 1/2 | NCT00473746 | Jun 2006 → Dec 2012 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00473512 | Nov 2005 → Nov 2008 | prostate neoplasm | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2115 trials | ||||||
| Phase 2 | NCT07645326 | Aug 2026 → Aug 2032 expected | metastatic prostate carcinoma | Georgetown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07650240 | Jul 2026 → Dec 2030 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07237269 | Apr 2026 → Apr 2033 expected | prostate cancer | University of Nebraska | Recruiting | No outcome recorded |
| Phase 2 | NCT07299292 | Dec 2025 → Dec 2026 expected | — | SMED Clinical Research | Recruiting | No outcome recorded |
| Phase 2 | NCT06392841 | Oct 2025 → Jan 2028 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, CHEK2-related cancer predisposition, Fanconi anemia complementation group A +2 | Qian Qin | Withdrawn | No outcome recorded |
| Phase 2 | NCT06894511 | Sep 2025 → Oct 2026 expected | prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05361915 | Sep 2025 → Jan 2028 | metastatic prostate carcinoma | Sorrento Therapeutics, Inc. | Suspended | No outcome recorded |
| Phase 2 | NCT07093866 | Jul 2025 → Dec 2026 expected | castration-resistant prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT06991556 | Jul 2025 → Mar 2032 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06527690 | Apr 2025 → Sep 2027 | castration-resistant prostate carcinoma | Latin American Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Show all 115 trials opens the full record — a long page | ||||||
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07641855 | Jun 2026 → Dec 2028 expected | castration-resistant prostate carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03348670 | Aug 2023 → Nov 2026 expected | prostate cancer | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07213674 | Nov 2025 → Jan 2030 expected | prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06855277 | Jul 2025 → Sep 2028 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05974774 | May 2025 → May 2035 expected | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT06650579 | Jan 2025 → Jul 2029 expected | prostate carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT06768255 | Jan 2025 → Dec 2028 expected | castration-resistant prostate carcinoma | Ding-Wei Ye | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03777982 | Apr 2020 → Feb 2024 | prostate cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 3 | NCT04139772 | Sep 2019 → Dec 2023 | castration-resistant prostate carcinoma | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 3 | NCT03903835 | Feb 2019 → Dec 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Karolinska Institutet | Recruiting | No outcome recorded |
| Phase 3 | NCT03009981 | Mar 2017 → Jun 2025 | prostate cancer | Alliance Foundation Trials, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT02887976 | Sep 2016 → Oct 2017 | prostate cancer | GU Research Network, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04056754 | Jul 2014 → Mar 2018 | castration-resistant prostate carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01949337 | Jan 2014 → Nov 2018 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | Alliance for Clinical Trials in Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT01957436 | Nov 2013 → Aug 2021 overdue | metastatic prostate carcinoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01715285 | Feb 2013 → Oct 2016 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01695135 | Aug 2012 → Jun 2014 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01517802 | Mar 2012 → Apr 2021 | breast cancer, prostate carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01591122 | Mar 2012 → Dec 2016 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00887198 | Apr 2009 → Mar 2014 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00638690 | May 2008 → Aug 2010 | prostate neoplasm | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07001709 | Apr 2024 → Dec 2025 overdue | prostate cancer | Deventer Ziekenhuis | Recruiting | No outcome recorded |
| Phase 4 | NCT03016741 | Mar 2017 → Jan 2023 overdue | castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02485691 | Nov 2015 → Mar 2019 | metastatic prostate carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02405858 | Apr 2015 → Dec 2017 | castration-resistant prostate carcinoma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06198387 | Jan 2024 → Sep 2025 overdue | metastatic prostate carcinoma | Changhai Hospital | Not yet recruiting | No outcome recorded |
| — | NCT03449719 | May 2018 → Sep 2021 | — | Lorenzo Livi | Unknown | No outcome recorded |
| — | NCT01961843 | Jan 2014 → Apr 2023 | prostate cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01858441 | Apr 2013 → Sep 2020 | — | Centre Antoine Lacassagne | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT05401214 | — | prostate carcinoma | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
| — | NCT01217697 | — | prostate cancer, urinary system neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Approved for marketing | No outcome recorded |
| — | NCT01834209 | — | prostate neoplasm | Janssen Research & Development, LLC | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 127 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 121 trials | ||||||
| Phase 1 | NCT06220864 Background | Feb 2024 → Dec 2027 expected | neoplasm | Synnovation Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06099990 Background | Oct 2023 → Dec 2028 expected | prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05177042 Background | May 2022 → Jul 2024 | metastatic prostate carcinoma | Arvinas Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05295927 Background | Mar → Sep 2022 | prostate neoplasm | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05084859 Background | Nov 2021 → Oct 2022 | castration-resistant prostate carcinoma, colorectal cancer, non-small cell lung carcinoma | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05022849 Background | Sep 2021 → Mar 2026 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04628988 Background | Jul 2021 → May 2023 | prostate neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04662580 Background | May 2021 → Dec 2026 expected | metastatic prostate carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04677855 Background | Mar 2021 → Oct 2023 | prostate cancer | Pellficure Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT04477512 Background | Feb → Sep 2021 | metastatic prostate carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04726332 Background | Feb 2021 → May 2024 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary, triple-negative breast carcinoma | Exelixis | Terminated | No outcome recorded |
| Phase 1 | NCT04421222 Background | Jun 2020 → Oct 2024 | prostate cancer | ESSA Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT04071262 Background | Dec 2019 → Feb 2021 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03110588 Background | May 2018 → Dec 2019 | metastatic prostate carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT02913196 Background | Dec 2016 → Jun 2021 | metastatic prostate carcinoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT02380313 Background | Oct 2015 → May 2017 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01884285 Background | Jul 2013 → Mar 2019 | castration-resistant prostate carcinoma, non-small cell squamous lung carcinoma, triple-negative breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01792687 Background | Feb 2013 → May 2014 | prostate cancer | Aragon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01741753 Background | Nov 2012 → Dec 2014 | prostate cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT01640093 Comparator | May → Jul 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01574937 Background | Apr 2012 → Dec 2014 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT07226986 Background | Dec 2025 → Jul 2028 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07104110 Background | Oct 2025 → Oct 2027 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06689163 Background | Dec 2024 → Nov 2025 overdue | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05405439 Background | Aug 2022 → Jul 2023 | castration-resistant prostate carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04839055 Comparator | Mar → Apr 2021 | castration-resistant prostate carcinoma | Jiangnan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05549778 Background | Jan 2021 → Jan 2023 | castration-resistant prostate carcinoma | Jiangnan University | Completed | No outcome recorded |
| Phase 1/2 | NCT04458311 Background | Dec 2020 → Apr 2023 | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Terminated | No outcome recorded |
| Phase 1/2 | NCT04194554 Background | Nov 2020 → May 2027 expected | prostate cancer | University of Michigan Rogel Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04556617 Background | Sep 2020 → May 2022 | castration-resistant prostate carcinoma | Opna Bio LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT04179864 Background | Nov 2019 → Nov 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Epizyme, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03568656 Background | Jul 2018 → Jul 2025 | breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma | CellCentric Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02711137 Background | May 2016 → Feb 2019 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01848067 Background | Aug 2013 → Mar 2015 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT01717898 Background | Jan → Sep 2013 | castration-resistant prostate carcinoma | Charles Ryan | Terminated | No outcome recorded |
| Phase 246 trials | ||||||
| Phase 2 | NCT07287150 Comparator | Mar 2026 → Mar 2028 expected | prostate carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT07230106 Background | Dec 2025 → Dec 2028 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07005154 Comparator | Jun 2025 → May 2032 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07553988 Comparator | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05593497 Background | May 2024 → May 2027 expected | prostate cancer | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT06212583 Comparator | Apr 2024 → Dec 2028 expected | prostate cancer | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05551117 Comparator | Jun 2023 → Jul 2024 | anal carcinoma, castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma, laryngeal squamous cell carcinoma +4 | MacroGenics | Terminated | No outcome recorded |
| Phase 2 | NCT05705700 Background | Feb 2023 → Jan 2030 | prostate cancer | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT05588609 Background | Nov 2022 → Jul 2025 | castration-resistant prostate carcinoma | Partner Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05422911 Comparator | Aug 2022 → Dec 2027 expected | metastatic malignant neoplasm, prostate carcinoma | Sun Pharmaceutical Industries, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05212857 Background | Apr 2022 → Feb 2024 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05167175 Background | Mar 2022 → Dec 2024 | metastatic prostate carcinoma | Hongqian Guo | Unknown | No outcome recorded |
| Phase 2 | NCT05156450 Background | Jan 2022 → Oct 2023 | castration-resistant prostate carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04812366 Comparator | Sep 2021 → Apr 2026 overdue | prostate cancer | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2 | NCT04869488 Comparator | Jul 2021 → Feb 2023 | metastatic prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04992026 Background | Jan 2021 → Dec 2024 | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04267887 Background | May 2020 → Jan 2028 expected | metastatic prostate carcinoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04207255 Background | Mar 2020 → Aug 2023 | prostate cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT04262154 Background | Mar 2020 → Jul 2025 overdue | metastatic prostate carcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03763253 Background | Apr 2019 → Aug 2026 overdue | metastatic prostate carcinoma | Imperial College London | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03770455 Background | Jan 2019 → Dec 2020 | castration-resistant prostate carcinoma | Jodi Layton, MD | Terminated | No outcome recorded |
| Phase 2 | NCT02789878 Background | Jan 2019 → Apr 2022 | prostate cancer | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03556904 Background | Dec 2018 → Jul 2023 | prostate cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03414034 Background | Aug 2018 → Oct 2023 | prostate carcinoma | Cardiff Oncology | Completed | No outcome recorded |
| Phase 2 | NCT03458247 Comparator | Jun 2018 → Apr 2021 | prostate cancer | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT03565835 Background | Jun 2018 → Nov 2021 | prostate neoplasm | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03418324 Background | Mar 2018 → Nov 2019 | prostate cancer | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02949284 Comparator | Jun 2017 → Jun 2026 overdue | prostate adenocarcinoma | Rutgers, The State University of New Jersey | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03012321 Comparator | Jan 2017 → Oct 2023 overdue | DNA repair disease, castration-resistant prostate carcinoma, metastatic prostate carcinoma | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02960022 Background | Dec 2016 → Jul 2029 expected | prostate cancer | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT02543255 Background | Sep 2016 → May 2021 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT02737332 Comparator | Mar 2016 → Feb 2017 | prostate cancer | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02758132 Comparator | Mar → Sep 2016 | prostate cancer | University of Hawaii | Terminated | No outcome recorded |
| Phase 2 | NCT02379390 Comparator | Jun 2015 → May 2018 | metastatic prostate carcinoma | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT02254785 Comparator | Oct 2014 → May 2020 | castration-resistant prostate carcinoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT02077634 Comparator | May 2014 → Apr 2019 | prostate cancer | Saarland University | Completed | No outcome recorded |
| Phase 2 | NCT01972217 Comparator | Apr 2014 → Sep 2017 | prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01995058 Background | Feb → Nov 2014 | castration-resistant prostate carcinoma | Exelixis | Terminated | No outcome recorded |
| Phase 2 | NCT01946165 Background | Oct 2013 → Jul 2017 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01681433 Background | Dec 2012 → Jun 2017 | prostate carcinoma | Costantine Albany | Terminated | No outcome recorded |
| Phase 2 | NCT01685125 Background | Sep 2012 → Mar 2016 | hormone-resistant prostate carcinoma | University of Southern California | Unknown | No outcome recorded |
| Phase 2 | NCT01650194 Background | Jul 2012 → Jan 2018 | prostate carcinoma | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01553188 Background | Feb 2012 → Apr 2017 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 expected | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03706365 Background | Nov 2018 → Jan 2024 overdue | prostate cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03295565 Comparator | May 2017 → Dec 2020 | metastatic neoplasm, metastatic prostate carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 337 trials | ||||||
| Phase 3 | NCT07711002 Background | Oct 2026 → Jun 2031 expected | metastatic prostate carcinoma | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07620574 Background | May 2026 → May 2030 expected | colorectal cancer, differentiated thyroid carcinoma, hepatocellular carcinoma, pancreatic neuroendocrine tumor +2 | Exelixis | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07611110 Comparator | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07311694 Comparator | Feb 2026 → Dec 2027 expected | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06952803 Background | Aug 2025 → Mar 2033 expected | prostate cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06592924 Background | May 2025 → Mar 2031 expected | prostate adenocarcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06764485 Comparator | Mar 2025 → Sep 2027 expected | prostate carcinoma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06691984 Comparator | Dec 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06496581 Background | Sep 2024 → Feb 2033 expected | metastatic prostate carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 3 | NCT06520345 Background | Jul 2024 → Dec 2027 expected | prostate carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06320067 Background | Jun 2024 → Apr 2031 expected | metastatic prostate carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT06136624 Comparator | Dec 2023 → Aug 2028 expected | metastatic prostate carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06136650 Comparator | Dec 2023 → May 2028 expected | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06120491 Background | Nov 2023 → Sep 2027 expected | metastatic prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04876651 Comparator | Aug 2023 → Jul 2025 | metastatic prostate carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Terminated | No outcome recorded |
| Phase 3 | NCT05288166 Background | Apr 2022 → Feb 2024 overdue | metastatic neoplasm, prostate neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05204927 Comparator | Feb 2022 → Aug 2024 overdue | metastatic prostate carcinoma | Curium US LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04844749 Comparator | Jun 2021 → May 2023 | castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05171816 Background | Jun 2021 → Jan 2024 overdue | prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04689828 Comparator | Jun 2021 → Oct 2022 overdue | prostate neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04887506 Comparator | May 2021 → Oct 2022 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Tavanta Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04691804 Comparator | Mar 2021 → Dec 2026 expected | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04647526 Comparator | Feb 2021 → Nov 2023 overdue | castration-resistant prostate carcinoma | POINT Biopharma | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04446117 Comparator | Oct 2020 → Apr 2024 overdue | metastatic prostate carcinoma, prostate adenocarcinoma | Exelixis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04497844 Background | Sep 2020 → Jan 2025 overdue | metastatic prostate carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04493853 Background | Jul 2020 → Oct 2024 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04115007 Comparator | Jun 2020 → Jun 2026 overdue | prostate carcinoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03834519 Comparator | May 2019 → Mar 2022 | prostate neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03748641 Background | Jan 2019 → Oct 2021 overdue | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03732820 Background | Oct 2018 → Jul 2021 overdue | prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2028 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT03072238 Background | Jun 2017 → Mar 2020 | metastatic prostate carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02975934 Comparator | Jun 2017 → Aug 2022 | castration-resistant prostate carcinoma | pharmaand GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02987543 Comparator | Feb 2017 → Jun 2019 | prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT06350825 Comparator | Jan 2016 → Dec 2027 expected | metastatic prostate carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT02257736 Background | Nov 2014 → Mar 2018 overdue | prostate neoplasm | Aragon Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02043678 Background | Mar 2014 → Feb 2018 | prostate neoplasm | Bayer | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05457257 Comparator | Jul 2022 → Oct 2024 overdue | castration-resistant prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04597125 Comparator | Nov 2020 → Nov 2025 overdue | prostate carcinoma | Bayer | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01995513 Background | Oct 2013 → Nov 2016 | prostate cancer | Pfizer | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07483658 Background | May 2026 → Dec 2029 expected | prostate cancer | CHU de Quebec-Universite Laval | Recruiting | No outcome recorded |
| — | NCT05707468 Comparator | May 2024 → Mar 2025 overdue | metastatic prostate carcinoma | Changhai Hospital | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-19 | Roche Global Development | Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints roche.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 351 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abiraterone acetate | “This is a randomized (study drug is assigned by chance), open-label (all people know the identity of the intervention), parallel-arm, multicenter, phase 2 study of treatment...” NCT01867710 ↗191“This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration...” NCT01688492 ↗ “These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily.” NCT05574712 ↗ “A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy” NCT01795703 ↗ “Abiraterone acetate (AA) has been approved for the treatment of mCRPC after docetaxel progression at doses of 1.000 mg per day taken in fasting conditions.” NCT02730975 ↗ “1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions” NCT01897389 ↗ “Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.” NCT06527690 ↗ “The purpose of this study is to evaluate systemic exposure of abiraterone acetate in adult male patients with severe hepatic impairment” NCT01516047 ↗ “The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi).” NCT04597125 ↗ “ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet for Oral” NCT03348670 ↗ “Oral abiraterone acetate will be administered as a single daily dose (500, 750, or 1000 mg).” NCT01400555 ↗ “Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day)” NCT02160353 ↗ “BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.” NCT04889651 ↗ |
| Known as | abiraterone | “The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous...” NCT03110588 ↗158“Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although other standard agents (e.g. docetaxel,...” NCT03556904 ↗ “Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be...” NCT05022849 ↗ “Darolutamide is the preferred ARPI for this study; however, patients may receive abiraterone, apalutamide, or enzalutamide at the discretion of their oncologist and based on...” NCT07645326 ↗ “Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).” NCT03763253 ↗ “Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).” NCT04115007 ↗ “Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations” NCT04399876 ↗ “Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC).” PMID 38926066 ↗ Jun 2024 “ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care” NCT06496581 ↗ “In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide.” NCT06655259 ↗ “Abiraterone acetate (referred to as abiraterone) is a drug currently under development for use in treating men with CRPC.” NCT01217697 ↗ “or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling)” PMID 39293462 ↗ Sep 2024 “Patients with pelvic nodal disease may receive abiraterone and prednisone for 24 months as per STAMPEDE protocol.” NCT07483658 ↗ “Triplet or doublet therapy (ie. docetaxel/abiraterone, apalutamide，Rezvilutamide，darolutamide，enzalutamide)” NCT06350825 ↗ “Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide).” NCT06320067 ↗ “Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)” NCT03696186 ↗ “During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally.” NCT05189457 ↗ “In this trial, participants will be given either enzalutamide or abiraterone.” NCT06855277 ↗ “ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)” NCT05974774 ↗ “Abiraterone plus Polaprezinc for 6 months” NCT05549778 ↗ “One or combination of agents: Abiraterone” NCT02788201 ↗ “enzalutamide or abiraterone” NCT04876651 ↗ |
| Known as | ATRS-2002 | “single Subcutaneous (SC) dose of ATRS-2002 (abiraterone acetate), or a single oral dose of the commercially available formulation of abiraterone acetate (Zytiga®).” NCT04879589 ↗ |
| Known as | BR9004 | “BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.” NCT04889651 ↗ |
| Known as | BR9004-1 | “BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea” NCT04889651 ↗ |
| Known as | CB7630 | “The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate)...” NCT00600535 ↗6“The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in...” NCT00473746 ↗ “A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic...” NCT00887198 ↗ “A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy” NCT00474383 ↗ “An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001” NCT01664728 ↗ “A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer” NCT00910754 ↗ “Abiraterone Acetate (CB7630)” NCT00638690 ↗ |
| Known as | JNJ-212082 | “A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate...” NCT01695135 ↗3“Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer...” NCT01381874 ↗ “Abiraterone Acetate (JNJ-212082) Plus Prednisone” NCT01591122 ↗ |
| Known as | JNJ-589485 | “An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone (JNJ-589485) Following Administration of Abiraterone...” NCT01588782 ↗1“A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone...” NCT01873001 ↗ |
| Known as | OAA | “ZYTIGA®, the originator abiraterone acetate (OAA), in patients with metastatic CRPC.” PMID 40346626 ↗ May 2025 |
| Known as | SoluMatrix | “SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor” NCT02887976 ↗ |
| Known as | Zygita | “abiraterone (Zygita®, "Zytiga is a trademark of Janssen Biotech, Inc.")” NCT02380313 ↗ |
| Known as | Zytiga | “In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat...” NCT01751451 ↗7“The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi).” NCT04597125 ↗ “For novel hormone therapy, there are also 3 options available. 1. "Abiraterone"/ "ZYTIGA®".” NCT06832774 ↗ “Abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)” NCT04735913 ↗ “abiraterone (Zygita®, "Zytiga is a trademark of Janssen Biotech, Inc.")” NCT02380313 ↗ “Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets” NCT05413421 ↗ |
| Action | Inhibit | “abiraterone, a steroid synthesis inhibitor” NCT00268476 ↗ |
| Modality | Small molecule | “Abiraterone acetate is a steroidal irreversible inhibitor” NCT00638690 ↗ |
| Route | Oral | “oral abiraterone acetate (1000 mg daily)” PMID 34953525 ↗ Dec 2021 |
| Target | CYP17 | “inhibitor of CYP17” NCT00638690 ↗ |